610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma
Jean‐Charles Soria(Inserm), M.J. Millward, Ruth Plummer(National Health Service), Malcolm Ranson(Cancer Research UK Manchester Institute), Gérard Zalcman(Université Claude Bernard Lyon 1), Jolly Mazumdar(Howard Hughes Medical Institute), Sarah P. Blagden(Churchill Hospital), Sonya R Murray(Providence College), D. Gibson, Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), K R Auger(Providence College), Ronald A. Fleming(Research Triangle Park Foundation), Hui Gan(Austin Hospital), Vijay Peddareddigari(GlaxoSmithKline (United States)), T.R. Jeffry Evans(University of Glasgow)
Cited by 8
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664